SCN5A mutation type and topology are associated with the risk of ventricular arrhythmia by sodium channel blockers

SCN5A mutation is associated with an increased risk of drug-induced ventricular arrhythmia in patients without baseline type-1 ECG. In particular, Snon-missense and Smissense-TP are at high risk.